Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which
has limited its clinical use. Our previous study found variability when laboratories used their …

The 2012 IMPAKT task force investigated the medical usefulness of current methods for the
classification of breast cancer into the 'intrinsic'molecular subtypes (luminal A, luminal B …

The present review discusses recent work on melatonin-mediated circadian regulation, the
metabolic and molecular signaling mechanisms that are involved in human breast cancer …

Introduction Breast cancer remains a significant scientific, clinical and societal challenge.
This gap analysis has reviewed and critically assessed enduring issues and new challenges …

Purpose Tumor-associated macrophages (TAMs) are activated macrophages associated
with tumor progression in various cancers. TAMs can polarize M1 or M2 type. M1 has a pro …

Breast cancer is a highly heterogeneous disease due to its diverse morphological features,
the variable clinical outcome and the response to different therapeutic options. It is therefore …

Here we report for the first time the relation between breast cancer subtypes and 10‐year
recurrence rates and mortality in the Netherlands. All operated women diagnosed with …

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response
to treatment after months rather than years of follow-up. However, significant variability exists …

Abstract Background The proliferation marker Ki67 has been suggested as a promising
cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new …

Context.—The pioneering works on molecular classification (MC) by Perou and Sorlie et al
in the early 2000s using global gene expression profiling identified 5 intrinsic subtypes of …